« Back to Medicines list

Cyklokapron 500mg Tablets

  • Name:

    Cyklokapron 500mg Tablets

  • Company:
    info
  • Active Ingredients:

    Tranexamic Acid

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 02/04/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 12/2/2019

Click on this link to Download PDF directly

Mylan IRE Healthcare Limited

Mylan IRE Healthcare Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ALDARA 5% CREAM Active Ingredients Imiquimod
Medicine Name Ancotil 2.5g/250ml Solution for Infusion Active Ingredients Flucytosine
Medicine Name Brufen 400mg film-coated Tablets Active Ingredients Ibuprofen
Medicine Name Brufen 600mg film-coated tablets Active Ingredients Ibuprofen
Medicine Name Brufen Paediatric 100mg/5ml Oral Suspension Active Ingredients Ibuprofen
Medicine Name Brufen Retard 800mg prolonged release tablets Active Ingredients Ibuprofen
Medicine Name Calvidin 600mg/400IU Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cibacen 10mg Film Coated Tablet Active Ingredients Benazepril Hydrochloride
Medicine Name Cibacen 5mg Film Coated Tablets Active Ingredients Benazepril Hydrochloride
Medicine Name Clozaril 100mg Tablets Active Ingredients Clozapine
Medicine Name Clozaril 25mg Tablets Active Ingredients Clozapine
Medicine Name Colifoam 10% w/w Rectal Foam Active Ingredients Hydrocortisone Acetate
Medicine Name Colofac 135mg Tablets Active Ingredients Mebeverine Hydochloride
Medicine Name Creon 10000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon 25000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon for Children 5000 Gastro-resistant Granules Active Ingredients Pancreatin
Medicine Name Cyklokapron 500mg Tablets Active Ingredients Tranexamic Acid
Medicine Name Dalmane 15mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Dalmane 30mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Desunin 4000IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Desunin 800IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name DIFFLAM ORAL RINSE Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM SPRAY Active Ingredients Benzydamine Hydrochloride
Medicine Name Dona 1500mg Powder for Oral Solution Active Ingredients Glucosamine Sulfate, Sodium Chloride
Medicine Name Dona 500mg Capsules Active Ingredients Glucosamine Sulfate, Sodium Chloride
1 - 0 of 96 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 2 April 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 13 February 2019 PIL

Reasons for updating

  • New PIL for new product

Updated on 12 February 2019 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 August 2016 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 August 2016 SPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.3: Minor text change

In section 4.4: Addition of information regarding convulsions

In section 4.8: Addition of convulsions (frequency not known) to undesirable effects

In section 4.9: Addition of signs and symptoms to overdose

In section 10: Date of revision has changed

Updated on 11 August 2016 PIL

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.3: Minor text change

In section 4.4: Addition of information regarding convulsions

In section 4.8: Addition of convulsions (frequency not known) to undesirable effects

In section 4.9: Addition of signs and symptoms to overdose

In section 10: Date of revision has changed

Updated on 18 February 2015 SPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.8: Adverse reaction reporting statement has been added
In section 10: Date of revision has been changed

Updated on 18 February 2015 PIL

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.8: Adverse reaction reporting statement has been added
In section 10: Date of revision has been changed

Updated on 14 November 2013 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.2: Posology has been changed for children and those with renal insufficiency

In section 4.3: there has been additional contraindications added

In section 4.4: Additional information has been added for precautions and warnings

In section 4.8: Additional information regarding side effects has been added

In section 5.2: the pharmacokinetic properties has been expanded and additional text has been added

In section 10: the date of revision has changed

 

Updated on 14 November 2013 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.2: Posology has been changed for children and those with renal insufficiency

In section 4.3: there has been additional contraindications added

In section 4.4: Additional information has been added for precautions and warnings

In section 4.8: Additional information regarding side effects has been added

In section 5.2: the pharmacokinetic properties has been expanded and additional text has been added

In section 10: the date of revision has changed

 

Updated on 18 March 2011 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 7: the address of the MAH has changed
In section 10: the date of revision has changed to Feb 2011

Updated on 18 March 2011 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 7: the address of the MAH has changed
In section 10: the date of revision has changed to Feb 2011

Updated on 25 February 2008 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 7-The trading style of the Marketing Authorisation holder has been removed.

Updated on 25 February 2008 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Free text change information supplied by the pharmaceutical company

Section 7-The trading style of the Marketing Authorisation holder has been removed.

Updated on 2 October 2007 PIL

Reasons for updating

  • Change to marketing authorisation holder

Free text change information supplied by the pharmaceutical company

Change in MAH from
 
 
Meda AB,

 

Pipers Väg 2,

 

PO Box 906,

 

SE-170 09,

 

Solna,

 

Sweden.

 

Trading style:

 

Meda Pharmaceuticals,

 

Regus House,

 

Pegasus Business Park,

 

Herald Way,

 

Castle Donington,

 

Derbyshire DE74 2TZ

 

England.
 
to
 

Meda Health Sales Ireland Limited

Office 10 , Dunboyne Business Park

Dunboyne

Co Meath

Ireland

 

Trading as

 

Meda Pharma

Office 10 , Dunboyne Business Park

Dunboyne

Co Meath

Ireland
 
and change in PA number from
 
 
PA 1051/5/1
to
PA 1332/3/1
 

Updated on 2 October 2007 SPC

Reasons for updating

  • Change to marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change in MAH from
 
 
Meda AB,

 

Pipers Väg 2,

 

PO Box 906,

 

SE-170 09,

 

Solna,

 

Sweden.

 

Trading style:

 

Meda Pharmaceuticals,

 

Regus House,

 

Pegasus Business Park,

 

Herald Way,

 

Castle Donington,

 

Derbyshire DE74 2TZ

 

England.
 
to
 

Meda Health Sales Ireland Limited

Office 10 , Dunboyne Business Park

Dunboyne

Co Meath

Ireland

 

Trading as

 

Meda Pharma

Office 10 , Dunboyne Business Park

Dunboyne

Co Meath

Ireland
 
and change in PA number from
 
 
PA 1051/5/1
to
PA 1332/3/1
 

Updated on 17 August 2005 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 17 August 2005 PIL

Reasons for updating

  • New SPC for medicines.ie